+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 20 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are investigating the safety, tolerability, pharmacokinetics, and effectiveness of the drug IG3018 in people with high uric acid levels hyperuricemia, including those with and without chronic kidney disease CKD. This phase III clinical trial aims to better understand how IG3018 works in these groups and to explore appropriate dosing. The study is sponsored by Intelligem Therapeutics Australia Pty Ltd and includes participants aged 18 to 75 years. The trial has two parts. Part 1 is a randomized, double-blind, placebo-controlled dose escalation study in participants without CKD, testing increasing doses of IG3018 tablets 0.25 g, 0.5 g, and 1.0 g. Each dose cohort receives a single dose followed by four weeks of twice-daily maintenance dosing. Part 2 is an open-label study in participants with advanced predialysis CKD Stages 3a, 3b, and 4, who receive either 0.5 g or 1.0 g of IG3018 twice daily for four weeks. Participants will attend study visits for blood and urine sample collection to analyze drug levels and kidney function. Safety and efficacy will be assessed through laboratory tests, gout attack monitoring, and uric acid measurements over about 46 days. The study tracks changes in serum uric acid levels, kidney function markers, and drug pharmacokinetics. Participants must provide consent and follow study procedures throughout the treatment and monitoring periods.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
6 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.

Age: 18Years +All GendersPhase 3
325 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of NNC0487-0111 in people who have excess body weight and knee osteoarthritis. This study compares two doses of NNC0487-0111 given as weekly injections under the skin against a placebo, with the goal of helping participants lose weight and reduce knee pain. Participants have knee osteoarthritis confirmed by clinical and radiographic criteria and will follow a reduced-calorie diet and increased physical activity throughout the study. Participants will be randomly assigned to receive one of three treatments NNC0487-0111 dose level 1, NNC0487-0111 dose level 2, or a placebo, all given once weekly by subcutaneous injection using a pre-filled pen injector. The injections will be administered to the thigh, abdomen, or upper arm. All participants will be encouraged to follow a reduced-calorie diet and increase physical activity during the trial. The treatment period lasts for 80 weeks. Throughout the study, participants will have regular assessments of body weight, knee pain, physical function, and other health measures. Researchers will collect data on changes in weight, knee pain scores using the WOMAC index, physical function, blood pressure, cholesterol levels, blood sugar markers, and use of pain medication. Safety will be monitored through reporting of adverse events. The study is expected to continue until August 2028, with visits and evaluations occurring at scheduled intervals during the treatment period.

Age: 18Years +All GendersPhase 3
82 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of eloralintide in adults who are obese or overweight but do not have type 2 diabetes. This Phase 3 clinical trial aims to understand how eloralintide affects body weight and other health measures over time in this population. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all given by subcutaneous injection. The main phase of the study lasts about 75 weeks, and participants with prediabetes may continue into an extension phase for an additional 2 years to further assess long-term effects. During the study, participants will have regular visits for assessments including body weight, body fat, waist circumference, blood pressure, blood tests, and questionnaires on overall health. Researchers will monitor changes from baseline up to week 64 and longer for some measures, including the time to develop type 2 diabetes. Safety and medication use will also be tracked throughout the study period.

Age: 18Years +All GendersPhase 3
158 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of eloralintide compared with placebo in adults with persistent obesity or overweight. Participants may have type 2 diabetes or not, and all are on stable background therapy with a weekly incretin. This phase 3 randomized, double-blind study aims to understand the effects of eloralintide on body weight and related health outcomes. Participants will be randomly assigned to receive one of four doses of eloralintide or a placebo, all given by subcutaneous injection once weekly. The study treatment period lasts for 64 weeks, during which participants receive their assigned injections. This is a parallel group study, meaning each participant receives only one assigned treatment throughout the trial. Participant involvement spans about 80 weeks, including screening, treatment, and follow-up. Researchers will monitor changes in body weight, waist circumference, blood pressure, blood sugar, insulin, kidney function, inflammation markers, and quality of life using questionnaires. Safety and medication use will also be tracked. Visits and assessments will occur regularly to evaluate the treatment effects and participant well-being.

Age: 18Years +All GendersPhase 3
185 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety, side effects, and immune response triggered by various doses and formulations of investigational vaccines targeting Respiratory Syncytial Virus RSV and human Metapneumovirus hMPV in both younger and older healthy adults. This study involves different age groups including younger adults aged 18 to 49 years and older adults aged 60 to 80 years. The trial is conducted in phases to carefully monitor how these vaccines perform and their safety profiles. Participants receive a single dose of one of several investigational vaccines or a control vaccine or placebo, administered intramuscularly on Day 1. Younger adults receive one of several RSVhMPV or hMPV vaccine formulations at varying doses during Phase 1, while older adults receive similar vaccines in both Phase 1 and Phase 2. The study compares low, medium, and high doses across different vaccine types to understand immune responses and safety. During the study, participants are monitored for side effects and immune reactions from Day 1 through up to 24 months depending on the group. Assessments include tracking injection site reactions, systemic symptoms, adverse events, and laboratory tests before and after vaccination. Immune responses are measured by evaluating virus neutralization titers at several time points. Safety is closely observed with follow-up visits and reporting of any serious or medically attended events over the study duration.

Age: 18Years - 80YearsAll GendersPhase 1Phase 2
5 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of AZD6234 in adults who have obesity or are overweight with at least one weight-related health condition but do not have type 2 diabetes. This Phase III study is randomized, double-blind, and conducted across multiple centers worldwide. Participants will be assigned to receive either AZD6234 or a placebo to compare changes in body weight over 68 weeks of treatment. The study treatments involve subcutaneous injections once a week. Participants will receive one of two doses of AZD6234 or a matching placebo. The trial aims to assess how these treatments affect body weight, waist circumference, triglycerides, blood pressure, and fat mass, including measurements by DXA scans in a subset of participants. The treatment period lasts 68 weeks. During the study, participants will have regular visits for assessments including body weight, waist circumference, blood pressure, and blood tests. Some will have DXA scans to measure fat mass. Researchers will monitor safety and track the percentage change in body weight from the start of treatment. The total participation duration includes 68 weeks of treatment with monitoring at specified intervals.

Age: 18Years +All GendersPhase 3
220 locations
E

Actively Recruiting

The trial investigates how well AZD6234 works and its safety in adults who have Type 2 Diabetes Mellitus along with obesity or excess weight. This Phase III, global, randomized, double-blind study compares AZD6234 to a placebo to measure changes in body weight over 68 weeks of treatment. The study aims to better understand weight loss effects and related health changes in this population. Participants will be randomly assigned to one of three groups two different doses of AZD6234 or a placebo. The treatments are given by weekly subcutaneous injections. The study will last 68 weeks, during which participants receive their assigned injections and are monitored regularly for effectiveness and safety. Throughout the study, participants will attend multiple visits for evaluations, including body weight, waist circumference, blood pressure, and lab tests such as haemoglobin A1C and triglycerides. Some may undergo DXA scans to measure fat mass. Researchers will track changes from baseline to assess weight loss and metabolic effects. Safety and tolerability will also be monitored over the treatment period, which lasts about 68 weeks.

Age: 18Years +All GendersPhase 3
230 locations
R

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety, effectiveness, tolerability, and how the body processes OLX72021 in medically healthy men aged 18 to 59 years with mild to moderate androgenetic alopecia. This study is a Phase 1b2a randomized, placebo-controlled trial using multiple ascending doses of OLX72021 to better understand its effects on hair growth and safety in this population. Participants will be divided into groups receiving different doses of OLX72021 or placebo. In Phase 1b, two dose levels are given sequentially, each with 12 participants receiving three intradermal injections spaced 28 days apart. Phase 2a involves four groups, including one placebo group and three OLX72021 groups, with six intradermal treatments given 28 days apart. The study uses a double-blind design to compare the drug to placebo. Throughout the study, participants will have regular visits for treatment and monitoring, including assessments of adverse events, injection site reactions, and changes in hair count up to 24 weeks. Additional evaluations include pharmacokinetics, patient questionnaires about hair growth, and investigator assessments. Blood draws and safety monitoring will be performed, with the total study duration lasting up to approximately 24 weeks for primary outcome measurement.

Age: 18Years - 59YearsMALEPhase 1Phase 2
8 locations
E

Actively Recruiting

Healthy Volunteer

This research aims to evaluate the safety and immune response of two new formulations of the GSK 4-component Strep A vaccine in healthy young adults aged 18 to 25. The study will assess low, medium, and high doses of the vaccine combined with either an Alum or AS37 adjuvant. It is a phase 1 clinical trial to monitor immediate reactions and immune responses in participants receiving the vaccine for the first time. Participants are randomly assigned to one of seven groups receiving three doses of either low, medium, or high doses of the Strep A vaccine with Alum or AS37 adjuvant, or an Alum placebo. Doses are administered intramuscularly on Day 1, Day 31, and Day 121 in a sequential study design. The trial compares multiple doses and formulations to assess safety and immunogenicity. Throughout the study, participants will be monitored for solicited and unsolicited adverse events for up to 301 days. Laboratory tests, including blood samples, will be collected to assess immune responses at various time points before and after vaccinations. Participants will complete electronic diaries and attend follow-up visits to report any reactions and provide samples for detailed immunological analysis.

Age: 18Years - 25YearsAll GendersPhase 1
2 locations

1-10 of 20

1